Sarepta Therapeutics - SRPT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $150.14
  • Forecasted Upside: 22.18%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$122.89
▼ -1.58 (-1.27%)

This chart shows the closing price for SRPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sarepta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRPT

Analyst Price Target is $150.14
▲ +22.18% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $150.14, with a high forecast of $190.00 and a low forecast of $114.00. The average price target represents a 22.18% upside from the last price of $122.89.

This chart shows the closing price for SRPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Sarepta Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 16 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/6/2021
  • 0 strong buy ratings
  • 14 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/4/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
2/2/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/3/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/1/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/30/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/29/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/20/2023SVB LeerinkReiterated RatingOutperform$160.00Low
1/11/2023CowenBoost Target$114.00 ➝ $125.00Low
1/10/2023Needham & Company LLCBoost TargetBuy$158.00 ➝ $160.00Low
1/10/2023Credit Suisse GroupBoost TargetNeutral$101.00 ➝ $114.00Low
12/22/2022BTIG ResearchBoost TargetBuy$125.00 ➝ $160.00Low
12/16/2022UBS GroupUpgradeNeutral ➝ Buy$100.00 ➝ $158.00Low
12/13/2022Cantor FitzgeraldBoost Target$150.00 ➝ $174.00Low
11/3/2022Royal Bank of CanadaLower TargetOutperform$193.00 ➝ $190.00Low
11/3/2022The Goldman Sachs GroupBoost TargetBuy$152.00 ➝ $171.00Low
11/3/2022Credit Suisse GroupBoost TargetNeutral$93.00 ➝ $101.00Low
11/3/2022Robert W. BairdBoost Target$110.00 ➝ $152.00Low
11/3/2022Needham & Company LLCLower TargetBuy$162.00 ➝ $158.00Low
10/17/2022SVB LeerinkBoost TargetOutperform$126.00 ➝ $145.00Low
10/13/2022Morgan StanleyBoost TargetEqual Weight$135.00 ➝ $141.00Low
9/8/2022Morgan StanleyBoost TargetEqual Weight$100.00 ➝ $135.00Low
8/9/2022Royal Bank of CanadaBoost TargetOutperform$160.00 ➝ $182.00Low
8/3/2022Royal Bank of CanadaBoost TargetOutperform$156.00 ➝ $160.00N/A
8/3/2022GuggenheimBoost Target$100.00 ➝ $122.00Low
8/3/2022Morgan StanleyBoost TargetEqual Weight$80.00 ➝ $100.00Low
8/3/2022Credit Suisse GroupBoost TargetNeutral$90.00 ➝ $93.00Low
8/3/2022BarclaysBoost Target$104.00 ➝ $125.00Low
8/3/2022OppenheimerBoost Target$125.00 ➝ $150.00Low
7/29/2022Needham & Company LLCBoost TargetBuy$150.00 ➝ $162.00Low
6/24/2022Cantor FitzgeraldLower TargetOverweight$140.00 ➝ $128.00Low
6/24/2022Credit Suisse GroupLower TargetNeutral$95.00 ➝ $90.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$181.00 ➝ $155.00Medium
5/19/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $74.00Low
4/12/2022Morgan StanleyLower TargetEqual Weight$80.00 ➝ $77.00Low
3/7/2022Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $80.00High
3/2/2022BarclaysLower Target$125.00 ➝ $104.00Medium
3/2/2022Royal Bank of CanadaBoost TargetOutperform$145.00 ➝ $150.00High
2/1/2022Morgan StanleyLower TargetEqual Weight$92.00 ➝ $71.00Medium
1/18/2022Morgan StanleyBoost TargetEqual Weight$90.00 ➝ $92.00Low
1/11/2022Needham & Company LLCReiterated RatingBuy$150.00Medium
1/5/2022Needham & Company LLCLower TargetBuy$157.00 ➝ $150.00High
12/9/2021OppenheimerUpgradeMarket Perform ➝ Outperform$125.00Medium
11/5/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$88.00 ➝ $130.00Medium
11/4/2021Cantor FitzgeraldBoost TargetOverweight$128.00 ➝ $140.00High
11/4/2021Royal Bank of CanadaLower TargetOutperform$148.00 ➝ $145.00High
11/4/2021Needham & Company LLCLower TargetBuy$166.00 ➝ $157.00High
10/15/2021Berenberg BankReiterated RatingHold$90.00High
10/12/2021Credit Suisse GroupBoost TargetNeutral$75.00 ➝ $100.00High
10/12/2021SVB LeerinkReiterated RatingBuyHigh
10/12/2021Needham & Company LLCReiterated RatingBuyHigh
10/12/2021BTIG ResearchBoost TargetBuy$110.00 ➝ $125.00High
10/7/2021Robert W. BairdInitiated CoverageBuy$110.00Medium
9/15/2021GuggenheimUpgradeNeutral ➝ BuyHigh
8/16/2021Morgan StanleyLower TargetEqual Weight$93.00 ➝ $90.00High
8/5/2021Credit Suisse GroupBoost TargetNeutral$72.00 ➝ $75.00High
8/5/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$92.00 ➝ $87.00High
7/1/2021Berenberg BankInitiated CoverageHold$85.00Medium
6/14/2021BTIG ResearchInitiated CoverageBuy$110.00High
5/3/2021Needham & Company LLCInitiated CoverageBuy$166.00High
4/19/2021Morgan StanleyLower TargetEqual Weight$95.00 ➝ $93.00Low
4/16/2021William BlairReiterated RatingBuyLow
3/21/2021SVB LeerinkReiterated RatingBuyLow
3/2/2021Royal Bank of CanadaLower TargetOutperform$143.00 ➝ $132.00High
3/2/2021Needham & Company LLCReiterated RatingBuy$166.00High
3/2/2021SVB LeerinkBoost TargetOutperform$125.00 ➝ $126.00High
3/2/2021Piper SandlerLower TargetNeutral$140.00 ➝ $130.00High
2/26/2021MizuhoBoost TargetBuy$158.00 ➝ $160.00High
1/12/2021Smith Barney CitigroupDowngradeBuy ➝ NeutralHigh
1/11/2021UBS GroupDowngradeBuy ➝ NeutralHigh
1/8/2021OppenheimerReiterated RatingHold ➝ NeutralHigh
1/8/2021Credit Suisse GroupLower TargetNeutral$156.00 ➝ $73.00N/A
1/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$96.00N/A
1/8/2021Robert W. BairdLower TargetOutperform$223.00 ➝ $110.00N/A
1/8/2021CowenLower TargetOutperform$213.00 ➝ $114.00N/A
1/8/2021Needham & Company LLCLower TargetBuy$182.00 ➝ $166.00N/A
1/8/2021BarclaysLower TargetPositive ➝ Overweight$192.00 ➝ $125.00N/A
1/8/2021Cantor FitzgeraldLower TargetOverweight$217.00 ➝ $128.00N/A
1/8/2021Royal Bank of CanadaLower TargetOutperform$200.00 ➝ $143.00N/A
1/8/2021MizuhoLower TargetBuy$204.00 ➝ $158.00N/A
1/8/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$182.00 ➝ $95.00N/A
1/8/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
1/8/2021SVB LeerinkLower TargetOutperform$197.00 ➝ $125.00N/A
1/4/2021Piper SandlerBoost TargetOverweight$200.00 ➝ $240.00N/A
12/14/2020Smith Barney CitigroupBoost Target$190.00 ➝ $215.00Low
12/14/2020Credit Suisse GroupLower TargetNeutral$162.00 ➝ $156.00Medium
12/8/2020MizuhoBoost TargetBuy$192.00 ➝ $204.00High
11/11/2020Berenberg BankInitiated CoverageHold$140.00Medium
11/6/2020Credit Suisse GroupLower TargetNeutral$167.00 ➝ $162.00High
11/6/2020SVB LeerinkLower TargetOutperform$214.00 ➝ $197.00High
10/28/2020UBS GroupInitiated CoverageBuy$212.00Low
10/11/2020Royal Bank of CanadaReiterated RatingBuyLow
9/15/2020CitigroupBoost TargetBuy$177.00 ➝ $190.00Medium
8/31/2020HC WainwrightLower TargetBuy$260.00 ➝ $221.00Low
8/24/2020Raymond JamesInitiated CoverageOutperform$200.00High
8/21/2020Bank of AmericaLower TargetBuy$190.00 ➝ $189.00Medium
8/20/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$185.00 ➝ $167.00High
8/10/2020Morgan StanleyBoost TargetOverweight$172.00 ➝ $182.00Low
8/4/2020Piper SandlerLower TargetOverweight$206.00 ➝ $200.00Low
8/3/2020Credit Suisse GroupReiterated RatingBuyLow
6/22/2020JPMorgan Chase & Co.Boost TargetOverweight$160.00 ➝ $190.00Low
6/16/2020HC WainwrightReiterated RatingBuy$260.00Medium
6/10/2020Bank of AmericaReiterated RatingBuy$180.00High
6/8/2020HC WainwrightReiterated RatingBuy$260.00High
6/8/2020Robert W. BairdReiterated RatingBuy$192.00High
5/17/2020NomuraReiterated RatingBuy$230.00High
5/15/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
5/15/2020Robert W. BairdReiterated RatingBuy$192.00High
5/15/2020HC WainwrightReiterated RatingBuy$260.00High
5/7/2020Needham & Company LLCInitiated CoverageBuy$182.00High
5/7/2020Credit Suisse GroupReiterated RatingBuy$185.00High
5/7/2020OppenheimerReiterated RatingHoldHigh
5/6/2020Royal Bank of CanadaReiterated RatingBuy$182.00Low
4/30/2020MizuhoReiterated RatingBuy$183.00Low
4/15/2020Morgan StanleyLower TargetOverweight$173.00 ➝ $172.00Low
3/30/2020MizuhoInitiated CoverageBuy$183.00High
2/28/2020JPMorgan Chase & Co.Lower TargetOverweight$172.00 ➝ $160.00High
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$211.00 ➝ $217.00High
2/27/2020JMP SecuritiesLower TargetOutperform$280.00 ➝ $217.00High
2/25/2020Nomura SecuritiesReiterated RatingBuy$230.00High
1/23/2020SVB LeerinkReiterated RatingBuy$216.00Low
1/14/2020Credit Suisse GroupReiterated RatingBuy$185.00Low
1/14/2020CowenReiterated RatingBuy$213.00High
1/7/2020Bank of AmericaReiterated RatingBuy$187.00High
12/30/2019OppenheimerReiterated RatingHoldLow
12/26/2019CitigroupReiterated RatingBuy$177.00Low
12/25/2019Nomura SecuritiesReiterated RatingBuy$230.00Low
12/24/2019The Goldman Sachs GroupReiterated RatingBuy$180.00Low
12/24/2019Morgan StanleyBoost TargetOverweight$160.00 ➝ $173.00Low
12/24/2019Credit Suisse GroupReiterated RatingOverweight ➝ Outperform$190.00 ➝ $185.00Low
12/23/2019Piper Jaffray CompaniesReiterated RatingBuy$210.00N/A
12/23/2019Royal Bank of CanadaLower TargetOutperform$215.00 ➝ $200.00Medium
12/20/2019Robert W. BairdBoost TargetOutperform$181.00 ➝ $192.00Low
12/18/2019Nomura SecuritiesReiterated RatingBuy$230.00Low
12/17/2019CitigroupBoost TargetBuy$167.00 ➝ $177.00Low
12/15/2019CowenInitiated CoverageBuy$213.00Medium
12/15/2019BarclaysReiterated RatingBuy$202.00Medium
12/13/2019HC WainwrightBoost Target$160.00 ➝ $260.00Low
12/13/2019Cantor FitzgeraldBoost TargetOverweight$175.00 ➝ $211.00High
12/13/2019SVB LeerinkReiterated RatingOutperform$186.00 ➝ $216.00Medium
12/13/2019Piper Jaffray CompaniesReiterated RatingBuy$185.00 ➝ $210.00High
12/13/2019Credit Suisse GroupBoost TargetOutperform$185.00 ➝ $190.00High
12/13/2019Janney Montgomery ScottBoost TargetBuy$160.00 ➝ $175.00High
12/13/2019Royal Bank of CanadaReiterated RatingOutperform$215.00High
11/18/2019CitigroupLower TargetBuy ➝ Positive$180.00 ➝ $167.00Low
11/8/2019Credit Suisse GroupLower TargetOutperform$201.00 ➝ $185.00High
11/1/2019GuggenheimInitiated CoverageBuy$183.00High
10/11/2019Morgan StanleyLower TargetOverweight$220.00 ➝ $160.00Low
10/8/2019OppenheimerReiterated RatingHoldLow
9/27/2019Piper Jaffray CompaniesSet TargetBuy$185.00Low
9/27/2019CitigroupLower TargetBuy$185.00 ➝ $180.00Medium
9/24/2019Royal Bank of CanadaSet TargetBuy$204.00High
9/13/2019HC WainwrightSet TargetBuy$160.00Low
8/21/2019Needham & Company LLCLower TargetBuy$196.00 ➝ $170.00Low
8/20/2019Royal Bank of CanadaLower TargetOutperform$204.00Low
8/20/2019Cantor FitzgeraldLower TargetOverweight$231.00 ➝ $175.00Low
8/20/2019Robert W. BairdLower TargetOutperform$202.00 ➝ $181.00High
8/20/2019Bank of AmericaLower TargetBuy$200.00 ➝ $189.00High
8/20/2019Credit Suisse GroupLower TargetOutperform$207.00 ➝ $201.00High
8/20/2019Janney Montgomery ScottLower TargetBuy$200.00 ➝ $175.00High
8/20/2019HC WainwrightReiterated RatingBuy$160.00 ➝ $267.00High
8/20/2019Piper Jaffray CompaniesLower TargetOverweight$208.00 ➝ $185.00High
8/9/2019William BlairReiterated RatingBuyLow
8/8/2019Evercore ISIReiterated RatingBuy$200.00High
7/9/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$165.00 ➝ $220.00Medium
7/1/2019Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$188.00 ➝ $220.00Low
6/17/2019HC WainwrightSet TargetBuy$267.00Low
5/16/2019CitigroupLower TargetBuy$201.00 ➝ $190.00Medium
5/14/2019Morgan StanleyLower TargetOverweight$169.00 ➝ $165.00Medium
5/9/2019Royal Bank of CanadaLower TargetOutperform$191.00 ➝ $188.00High
4/17/2019BTIG ResearchSet TargetBuy$190.00High
4/11/2019Evercore ISIInitiated CoverageOutperform$175.00High
3/31/2019CowenReiterated RatingBuy$213.00Low
3/28/2019Piper Jaffray CompaniesBoost TargetOverweight$200.00 ➝ $208.00Low
3/12/2019BMO Capital MarketsInitiated CoverageOutperformLow
3/11/2019Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$189.00 ➝ $207.00Low
3/5/2019SVB LeerinkReiterated RatingOutperformLow
3/4/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$161.00 ➝ $169.00Low
3/1/2019CitigroupBoost TargetBuy ➝ Buy$188.00 ➝ $201.00Low
2/28/2019Nomura SecuritiesBoost TargetBuy ➝ Buy$205.00 ➝ $230.00Low
2/28/2019Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$217.00 ➝ $231.00High
2/27/2019JMP SecuritiesReiterated RatingBuy$270.00High
2/22/2019Cantor FitzgeraldReiterated RatingBuyHigh
2/5/2019BTIG ResearchSet TargetBuy$190.00Low
1/30/2019Piper Jaffray CompaniesBoost TargetOverweight$168.00 ➝ $200.00High
1/17/2019Royal Bank of CanadaReiterated RatingOutperform$164.00Low
1/8/2019Janney Montgomery ScottSet TargetBuy$200.00Medium
1/4/2019HC WainwrightSet TargetBuy$267.00High
12/28/2018BTIG ResearchSet TargetBuy$190.00Medium
12/10/2018HC WainwrightSet TargetBuy$267.00Low
11/26/2018Cantor FitzgeraldReiterated RatingBuy$217.00High
11/6/2018CitigroupBoost TargetBuy ➝ Buy$174.00 ➝ $188.00Medium
10/26/2018Piper Jaffray CompaniesLower TargetOverweight$189.00 ➝ $168.00Low
10/12/2018Sanford C. BernsteinInitiated CoverageOutperform$170.00High
10/4/2018Credit Suisse GroupBoost Target$178.00 ➝ $189.00High
10/4/2018Piper Jaffray CompaniesReiterated RatingOverweight$189.00High
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$217.00High
9/26/2018Royal Bank of CanadaReiterated RatingOutperform$187.00 ➝ $200.00Medium
9/24/2018BTIG ResearchSet TargetBuy$190.00Low
9/24/2018Needham & Company LLCLower TargetBuy$196.00Low
9/21/2018HC WainwrightReiterated RatingBuy$267.00High
9/14/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$199.00Low
9/6/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$178.00Medium
9/4/2018HC WainwrightSet TargetBuy$267.00High
8/14/2018CitigroupInitiated CoverageBuyMedium
8/9/2018CowenReiterated RatingBuy$178.00High
8/9/2018HC WainwrightSet TargetBuy$267.00High
8/1/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$163.00Low
7/18/2018HC WainwrightSet TargetBuy$267.00Medium
6/25/2018JMP SecuritiesBoost TargetOutperform$275.00Low
6/22/2018SunTrust BanksBoost TargetBuy$176.00High
6/21/2018Nomura SecuritiesBoost TargetBuy ➝ Buy$131.00 ➝ $205.00Medium
6/21/2018Robert W. BairdReiterated RatingOutperform ➝ Outperform$120.00 ➝ $202.00Medium
6/20/2018WBB SecuritiesReiterated RatingBuyLow
6/20/2018Royal Bank of CanadaBoost TargetOutperform$189.00Medium
6/20/2018Needham & Company LLCBoost TargetBuy$109.00 ➝ $204.00Medium
6/20/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$91.00 ➝ $163.00High
6/20/2018CowenReiterated RatingOutperform$178.00High
6/20/2018SVB LeerinkReiterated RatingOutperform ➝ OutperformHigh
6/20/2018BarclaysReiterated RatingOverweight$180.00High
6/20/2018Piper Jaffray CompaniesReiterated RatingOverweight$168.00High
6/19/2018William BlairReiterated RatingBuyHigh
6/19/2018JPMorgan Chase & Co.Reiterated RatingOverweightHigh
6/19/2018HC WainwrightBoost TargetBuy$96.00 ➝ $267.00High
6/15/2018BTIG ResearchInitiated CoverageBuy$120.00High
6/11/2018HC WainwrightReiterated RatingBuy$96.00Low
5/18/2018The Goldman Sachs GroupBoost TargetBuy$84.00 ➝ $127.00Low
5/15/2018SVB LeerinkBoost TargetHold ➝ Outperform$88.00 ➝ $121.00Low
5/11/2018BarclaysUpgradeEqual Weight ➝ Overweight$55.00 ➝ $107.00Low
5/7/2018Needham & Company LLCBoost TargetIn-Line ➝ Buy$75.00 ➝ $109.00Low
5/4/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$87.00 ➝ $91.00High
5/4/2018Credit Suisse GroupSet TargetOutperform ➝ Buy$100.00 ➝ $92.00High
5/4/2018Nomura SecuritiesBoost TargetBuy$131.00High
5/4/2018Royal Bank of CanadaBoost TargetOutperform ➝ Positive$98.00High
5/4/2018JMP SecuritiesReiterated RatingOutperform$95.00 ➝ $90.00High
5/4/2018HC WainwrightSet TargetBuy ➝ Buy$90.00 ➝ $96.00High
5/4/2018OppenheimerDowngradeOutperform ➝ Market PerformHigh
5/4/2018UBS GroupDowngradeOutperform ➝ Market PerformHigh
4/23/2018HC WainwrightReiterated RatingBuy$92.00High
4/5/2018Credit Suisse GroupSet TargetBuy$100.00Medium
3/21/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$64.00 ➝ $87.00Medium
3/16/2018SunTrust BanksBoost TargetBuy$95.00Medium
3/14/2018Royal Bank of CanadaReiterated RatingBuy$91.00Medium
3/14/2018JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$75.00 ➝ $95.00Low
3/13/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$81.00 ➝ $100.00Low
3/13/2018SVB LeerinkReiterated RatingOutperform ➝ Positive$79.00 ➝ $92.00Medium
3/12/2018Credit Suisse GroupReiterated RatingHold$81.00High
3/12/2018HC WainwrightBoost TargetBuy ➝ Buy$75.00 ➝ $92.00High
3/12/2018Piper Jaffray CompaniesReiterated RatingOverweight$83.00 ➝ $76.12High
3/8/2018SunTrust BanksBoost TargetBuy$76.00Medium
3/6/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$63.00 ➝ $64.00Low
3/2/2018Credit Suisse GroupSet TargetBuy$81.00Low
3/2/2018Nomura SecuritiesBoost TargetBuy$96.00High
3/2/2018HC WainwrightSet TargetBuy$75.00High
3/2/2018Piper Jaffray CompaniesReiterated RatingOverweightHigh
2/21/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$63.00 ➝ $75.00Low
2/12/2018HC WainwrightSet TargetBuy$75.00High
2/5/2018William BlairReiterated RatingOutperformHigh
(Data available from 1/28/2018 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/2/2022
  • 9 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/1/2022
  • 10 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/31/2022
  • 6 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/30/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2022
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
11/29/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2022
  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2023

Current Sentiment

  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Sarepta Therapeutics logo
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $122.89
Low: $121.89
High: $126.11

50 Day Range

MA: $123.52
Low: $110.55
High: $132.13

52 Week Range

Now: $122.89
Low: $61.28
High: $134.08

Volume

724,377 shs

Average Volume

1,074,121 shs

Market Capitalization

$10.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?

The following sell-side analysts have issued stock ratings on Sarepta Therapeutics in the last year: Barclays PLC, BTIG Research, Cantor Fitzgerald, Cowen Inc, Credit Suisse Group AG, Guggenheim, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for SRPT.

What is the current price target for Sarepta Therapeutics?

14 Wall Street analysts have set twelve-month price targets for Sarepta Therapeutics in the last year. Their average twelve-month price target is $150.14, suggesting a possible upside of 22.2%. Royal Bank of Canada has the highest price target set, predicting SRPT will reach $190.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $114.00 for Sarepta Therapeutics in the next year.
View the latest price targets for SRPT.

What is the current consensus analyst rating for Sarepta Therapeutics?

Sarepta Therapeutics currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRPT will outperform the market and that investors should add to their positions of Sarepta Therapeutics.
View the latest ratings for SRPT.

What other companies compete with Sarepta Therapeutics?

How do I contact Sarepta Therapeutics' investor relations team?

Sarepta Therapeutics' physical mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 274-4000 and its investor relations email address is [email protected] The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. Learn More about contacing Sarepta Therapeutics investor relations.